Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $524,232.94 in Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Christian Henry sold 331,793 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $1.58, for a total value of $524,232.94. Following the completion of the transaction, the insider owned 2,814,374 shares in the company, valued at $4,446,710.92. This represents a 10.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pacific Biosciences of California Price Performance

Shares of PACB opened at $1.61 on Friday. The stock has a market cap of $486.07 million, a P/E ratio of -0.87 and a beta of 2.27. Pacific Biosciences of California, Inc. has a 1 year low of $0.85 and a 1 year high of $2.73. The stock’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $1.78. The company has a current ratio of 6.24, a quick ratio of 5.40 and a debt-to-equity ratio of 17.88.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. The business had revenue of $44.65 million for the quarter, compared to the consensus estimate of $44.60 million. Pacific Biosciences of California had a negative net margin of 341.47% and a negative return on equity of 251.75%. On average, equities analysts predict that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on PACB. Stephens lifted their target price on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Pacific Biosciences of California from a “hold” rating to a “strong-buy” rating in a report on Thursday. Piper Sandler upped their price target on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Finally, Barclays increased their price objective on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pacific Biosciences of California currently has a consensus rating of “Moderate Buy” and an average price target of $2.20.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Genomics sector tailwind — Zacks published a roundup arguing genomics and synthetic-biology stocks deserve portfolio consideration in 2026, supporting longer‑term demand for sequencing platforms like PacBio’s systems. Genomics Stocks That Deserve a Place in Your Portfolio in 2026
• Positive Sentiment: Institutional accumulation — Large funds (ARK, Millennium, Renaissance, Casdin) materially increased or initiated PACB positions in recent quarters, which can provide liquidity support and signal conviction from some professional investors. MarketBeat PACB institutional holdings
• Neutral Sentiment: Upcoming investor event — PacBio will present at the TD Cowen Health Care Conference on March 2; management commentary there could provide updated commercialization or adoption metrics but nothing material has been released yet. PacBio at TD Cowen Conference
• Neutral Sentiment: Analyst mix — Recent notes show modest price‑target upgrades to ~$2.00 from some shops while consensus remains “Hold” with an average PT ~ $2.20; mixed coverage limits a catalytic analyst push. PACB analyst coverage
• Negative Sentiment: Large insider selling — Director/insider Christian O. Henry sold ~472,667 shares across Feb. 17–18 (~$753k proceeds). High‑profile insider sales at this scale often pressure the stock. Christian O. Henry Form 4
• Negative Sentiment: Additional insider exits — Oene Mark Van sold ~184,897 shares (Feb. 17–18) and Michele Farmer sold ~50,167 shares (Feb. 17–18); the combined insider reductions may amplify negative sentiment short‑term. Oene Mark Van Form 4 Michele Farmer Form 4

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PACB. Koss Olinger Consulting LLC lifted its position in Pacific Biosciences of California by 10.0% during the 2nd quarter. Koss Olinger Consulting LLC now owns 3,300,000 shares of the biotechnology company’s stock worth $4,092,000 after buying an additional 300,000 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Pacific Biosciences of California by 148.1% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 789,271 shares of the biotechnology company’s stock worth $979,000 after acquiring an additional 471,101 shares in the last quarter. Carret Asset Management LLC acquired a new position in Pacific Biosciences of California during the second quarter valued at approximately $391,000. Vestmark Advisory Solutions Inc. grew its stake in Pacific Biosciences of California by 89.9% in the second quarter. Vestmark Advisory Solutions Inc. now owns 1,294,186 shares of the biotechnology company’s stock valued at $1,605,000 after purchasing an additional 612,760 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Pacific Biosciences of California by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company’s stock worth $8,333,000 after purchasing an additional 401,637 shares in the last quarter.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.